Milestone Scientific Inc ((MLSS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Scientific’s latest earnings call struck a cautiously upbeat tone, as management balanced sharp cost cuts and narrowing losses against flat revenue and lingering reimbursement and execution risks. Leaders highlighted early traction in the CompuFlo medical segment, strong lead generation, and fresh financing, but stressed that meaningful growth still depends on scaling utilization and securing better Medicare coverage.
Operating Expense Reduction
Milestone delivered a notable reset in its cost structure, trimming operating expenses by about $1.3 million, or more than 30% year over year. Management framed these cuts as largely structural, arguing they create a leaner base from which any future revenue growth should translate more efficiently to the bottom line.
Improved Profitability Metrics
The impact of those savings showed up clearly in profitability, with operating loss shrinking to $828,000, a roughly 58% improvement from the prior-year period. Net loss similarly narrowed to $840,000, also about a 58% improvement, signaling that while the company remains in the red, its path toward breakeven is becoming more visible.
Stable Revenue Base
Total revenue held at approximately $2.2 million for the quarter, essentially flat versus last year despite a challenging backdrop. Management characterized this stability as resilience, noting that the business absorbed regional disruptions while maintaining its top line, though investors looking for acceleration will have to wait.
Strong Gross Margin
Gross profit reached $1.56 million, with gross margin a robust 72.3%, only modestly lower than 73.8% a year ago. The company emphasized that this high-margin profile provides attractive operating leverage potential if it can convert its growing pipeline into sustained revenue growth.
CompuFlo Medical Traction
The CompuFlo medical segment emerged as a key growth narrative, with revenue more than doubling year over year to roughly $108,000 in the quarter. Management pointed to this as evidence of early-stage adoption and growing clinical interest, even while acknowledging that the business is still nascent in absolute dollar terms.
Demand and Lead Generation
A ramped-up digital marketing push around CompuFlo generated 152 leads, equating to roughly 20–30 new potential customers per week. Executives noted that some hospital and clinic buyers are moving quickly from inquiry to purchase, with a subset of orders closing within just a week of initial contact.
Clinical and Reimbursement Progress
On the clinical front, Milestone now has more than eight physician partners engaged in its CompuFlo Advisor Program, with six additional physicians pending. The company has filed over 50 reimbursement claims across three Medicare Administrative Contractors, supported by a new reimbursement infrastructure and call center aimed at smoothing the path with Medicare.
Commercial Expansion
The commercial footprint expanded through the onboarding of seven to eight distribution partners, which together represent an estimated 20–30 salespeople in the field. Management said these distributors carry quotas and have begun placing initial orders, signaling a more leverageable sales model than the company had prior to this quarter.
Dental Ambassador Program Early Results
In the dental segment, Milestone’s ambassador program drew 173 applications and now counts 73 active ambassadors promoting its technology. Early activity included 25 new demos and multiple new sales, and the company is adding staff to better support ambassadors and drive more consistent conversion later in the year.
Balance Sheet Strengthening
Post-quarter, the company raised $2.15 million in a financing that management described as strategically targeted rather than dilutive for its own sake. The fresh capital is earmarked for sales expansion, inventory build, and digital marketing, while leadership emphasized continued discipline around spending and cash burn.
International Registration Progress
Milestone is also pushing internationally, pursuing new registrations that could open key markets by year-end. Management expects approvals in India and Mexico as soon as next quarter, with Japan targeted around September, potentially setting up a broader revenue base in the fourth quarter and beyond.
Revenue and Margin Headwinds
Despite operational progress, the quarter saw no top-line growth, with revenue flat at $2.2 million and a slight gross margin decline to 72.3%. The company flagged ongoing regional and mix pressures, but reiterated that margins remain strong enough to support attractive earnings leverage once growth reaccelerates.
Shipping Disruption Impact
A key drag on Q1 was about $200,000 of booked orders destined for the Middle East that could not ship due to conflict in the Strait of Hormuz. Management said most of these delayed orders have since shipped in the second quarter, though some remain in limbo, underscoring the business’s exposure to geopolitical logistics risks.
Early-Stage CompuFlo and Reimbursement Risk
While CompuFlo revenue more than doubled, management stressed that at roughly $108,000 for the quarter, it remains small and sensitive to scale. Adoption depends heavily on Medicare reimbursement progress, with the company seeking to move from a temporary coding status toward stronger long-term reimbursement, a process that carries execution and timing uncertainty.
Ambassador and Lead Conversion Challenges
The company acknowledged that only about 20–30% of dental ambassadors are currently active and driving tangible results, prompting plans for more focused management and hiring. Similarly, sales teams are struggling to convert the growing pool of inbound CompuFlo leads due to limited staffing and difficulty reaching physicians on tight schedules.
Expense Cuts Normalizing and Ongoing Cash Burn
Management cautioned that the dramatic expense reductions seen in Q1 will not repeat at the same scale in coming quarters, implying a more gradual improvement path from here. The company remains unprofitable, with an $840,000 net loss and continuing, albeit reduced, cash burn, making execution on growth and reimbursement milestones critical to extending its financial runway.
Forward-Looking Guidance and Outlook
Looking ahead, Milestone reaffirmed its 2026 revenue guidance of $9.8–$10.2 million, implying double-digit annual growth from today’s roughly $2.2 million quarterly run rate. Management also reiterated a target of reaching cash-flow breakeven in early 2027, leaning on accelerating CompuFlo growth, improved operating leverage, and the recent financing to fund targeted sales and marketing investments.
Milestone Scientific’s call painted a picture of a company tightening its cost base and building commercial infrastructure while waiting for its medical business and reimbursement efforts to unlock more material growth. Investors will likely focus on whether CompuFlo adoption, international expansion, and smoother logistics can convert today’s cautious optimism into sustained top-line momentum and a credible path to profitability.